CD274 and neoplasm: Notably, the magnitudes of survival benefits in subgroups of patients with tumor PD-L1 levels of ≥5% or ≥10% were similar to that with tumor PD-L1 level ≥ 1% with HR of 0.50 and 0.57, respectively.